Interestingly, a high EMI1/HER2 ratio correlated with better distant metastasis-free survival and overall survival of BC patients, while patients characterized by low EMILIN1 and high HER2 expression displayed a worse prognosis (Fig. 2e, f). This evidence concerns the gene ERBB2 and breast cancer.